Aurinia Pharmaceuticals Inc. Net Income
Aurinia Pharmaceuticals Inc. (AUPH) reported Net Income of $37.41 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was $37.41M, a 73.91% increase year-over-year.
- Aurinia Pharmaceuticals Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was $34.35M, a 47.17% increase year-over-year.
- Aurinia Pharmaceuticals Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $210.79M, a 14651.15% increase year-over-year.
- Aurinia Pharmaceuticals Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was $31.55M, a 119.87% increase year-over-year.
- Aurinia Pharmaceuticals Inc. net income (loss) attributable to parent for fiscal 2020 was -$102.68M.
- Aurinia Pharmaceuticals Inc. net income (loss) attributable to parent for fiscal 2019 was -$88.39M.
- Aurinia Pharmaceuticals Inc. net income (loss) attributable to parent for fiscal 2018 was -$53.08M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $37.41M 10-Q · filed 2026-08-06 | $71.77M 10-Q · filed 2026-08-06 | $282.56M derived: sum of 3 quarters · filed 2026-08-06 | $314.11M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $34.35M 10-Q · filed 2026-08-06 | $245.15M derived: sum of 2 quarters · filed 2026-08-06 | $276.70M derived: sum of 3 quarters · filed 2026-08-06 | $298.21M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $210.79M 10-K · filed 2026-02-26 | $242.34M derived: sum of 2 quarters · filed 2026-02-26 | $263.86M derived: sum of 3 quarters · filed 2026-08-06 | $287.20M DEF 14A · filed 2026-04-21 | $287.20M 10-K · filed 2026-02-26 |
| 2025-09-30 | $31.55M 10-K · filed 2026-02-26 | $53.06M derived: sum of 2 quarters · filed 2026-08-06 | $76.41M 10-Q · filed 2025-11-04 | $77.84M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $21.51M 10-Q · filed 2026-08-06 | $44.86M 10-Q · filed 2026-08-06 | $46.29M derived: sum of 3 quarters · filed 2026-08-06 | $60.64M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $23.34M 10-Q · filed 2026-08-06 | $24.77M derived: sum of 2 quarters · filed 2026-08-06 | $39.12M derived: sum of 3 quarters · filed 2026-08-06 | $39.84M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2024-12-31 | $1.43M 10-K · filed 2026-02-26 | $15.78M derived: sum of 2 quarters · filed 2026-02-26 | $16.50M derived: sum of 3 quarters · filed 2026-02-26 | $5.80M DEF 14A · filed 2026-04-21 | $5.75M 10-K · filed 2025-02-27 |
| 2024-09-30 | $14.35M 10-K · filed 2026-02-26 | $15.07M derived: sum of 2 quarters · filed 2026-02-26 | $4.32M 10-Q · filed 2025-11-04 | -$22.55M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $722.00K 10-K · filed 2026-02-26 | -$10.03M 10-Q · filed 2025-07-31 | -$36.90M derived: sum of 3 quarters · filed 2026-02-26 | -$50.35M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | -$10.75M 10-K · filed 2026-02-26 | -$37.62M derived: sum of 2 quarters · filed 2026-02-26 | -$51.07M derived: sum of 3 quarters · filed 2026-02-26 | -$62.56M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | -$26.88M 10-K · filed 2025-02-27 | -$40.32M derived: sum of 2 quarters · filed 2025-02-27 | -$51.81M derived: sum of 3 quarters · filed 2025-02-27 | -$78.00M DEF 14A · filed 2026-04-21 | -$78.02M 10-K · filed 2024-02-15 |
| 2023-09-30 | -$13.45M 10-K · filed 2025-02-27 | -$24.94M derived: sum of 2 quarters · filed 2025-02-27 | -$51.15M 10-Q · filed 2024-11-07 | -$77.19M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | -$11.49M 10-K · filed 2025-02-27 | -$37.70M 10-Q · filed 2024-08-01 | -$63.74M derived: sum of 3 quarters · filed 2025-02-27 | -$72.73M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | -$26.21M 10-K · filed 2025-02-27 | -$52.25M derived: sum of 2 quarters · filed 2025-02-27 | -$61.24M derived: sum of 3 quarters · filed 2025-02-27 | -$96.76M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | -$26.05M 10-K · filed 2024-02-15 | -$35.03M derived: sum of 2 quarters · filed 2024-02-15 | -$70.55M derived: sum of 3 quarters · filed 2024-02-15 | -$108.20M DEF 14A · filed 2026-04-21 | -$108.18M 10-K · filed 2023-02-28 |
| 2022-09-30 | -$8.99M 10-K · filed 2024-02-15 | -$44.50M derived: sum of 2 quarters · filed 2024-02-15 | -$82.13M 10-Q · filed 2023-11-02 | -$115.46M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2022-06-30 | -$35.52M 10-K · filed 2024-02-15 | -$73.14M 10-Q · filed 2023-08-03 | -$106.47M derived: sum of 3 quarters · filed 2024-02-15 | -$156.72M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2022-03-31 | -$37.63M 10-K · filed 2024-02-15 | -$70.95M derived: sum of 2 quarters · filed 2024-02-15 | -$121.21M derived: sum of 3 quarters · filed 2024-02-15 | -$168.22M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2021-12-31 | -$33.32M 10-K · filed 2023-02-28 | -$83.58M derived: sum of 2 quarters · filed 2023-02-28 | -$130.59M derived: sum of 3 quarters · filed 2023-02-28 | -$181.00M DEF 14A · filed 2026-04-21 | -$180.97M 10-K · filed 2022-02-28 |
| 2021-09-30 | -$50.26M 10-K · filed 2023-02-28 | -$97.27M derived: sum of 2 quarters · filed 2023-02-28 | -$147.64M 10-Q · filed 2022-11-03 | -$155.72M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | -$47.01M 10-K · filed 2023-02-28 | -$97.39M 10-Q · filed 2022-08-04 | -$105.46M derived: sum of 3 quarters · filed 2023-02-28 | -$147.59M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | -$50.38M 10-K · filed 2023-02-28 | -$58.45M derived: sum of 2 quarters · filed 2023-02-28 | -$100.58M derived: sum of 3 quarters · filed 2023-02-28 | -$127.13M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | -$8.07M 10-K · filed 2022-02-28 | -$50.20M derived: sum of 2 quarters · filed 2022-02-28 | -$76.75M derived: sum of 3 quarters · filed 2022-02-28 | -$102.68M 10-K · filed 2023-02-28 | |
| 2020-09-30 | -$42.13M 10-K · filed 2022-02-28 | -$68.67M derived: sum of 2 quarters · filed 2022-02-28 | -$94.61M 10-Q · filed 2021-11-03 | -$129.06M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-06-30 | -$26.54M 10-K · filed 2022-02-28 | -$52.48M 10-Q · filed 2021-08-05 | -$86.94M derived: sum of 3 quarters · filed 2022-02-28 | -$110.39M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-03-31 | -$25.93M 10-K · filed 2022-02-28 | -$60.39M derived: sum of 2 quarters · filed 2022-02-28 | -$83.84M derived: sum of 3 quarters · filed 2022-02-28 | -$100.22M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2019-12-31 | -$34.46M 10-K · filed 2021-02-24 | -$57.91M derived: sum of 2 quarters · filed 2021-02-24 | -$74.29M derived: sum of 3 quarters · filed 2021-02-24 | -$88.39M 10-K · filed 2022-02-28 | |
| 2019-09-30 | -$23.45M 10-K · filed 2021-02-24 | -$39.83M derived: sum of 2 quarters · filed 2021-02-24 | -$53.93M derived: sum of 3 quarters · filed 2021-02-24 | ||
| 2019-06-30 | -$16.38M 10-K · filed 2021-02-24 | -$30.47M derived: sum of 2 quarters · filed 2021-02-24 | |||
| 2019-03-31 | -$14.10M 10-K · filed 2021-02-24 | ||||
| 2018-12-31 | -$53.08M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |